Skip to content

uniQure QURE Other intangible assets—net

Other intangible assets—net at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$36M
Precigen logo
PrecigenPGEN
$2.86M-30.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$380.68M+221%
Biohaven logo
BiohavenBHVN
$18.4M0.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$174M-1.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's other intangible assets—net?
uniQure (QURE) reported other intangible assets—net of $69.99M in Q1 2026.
What is the long-term trend for uniQure's other intangible assets—net?
Over 2 years (2023 to 2025), uniQure's other intangible assets—net has grown at a 9.7% compound annual growth rate (CAGR), from $60.48M to $72.79M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.